Audited Financial Results along with Auditors Report for the Quarter and Year ended March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natural Biocon reported a steep revenue decline for FY2026 with total income of Rs 2.55 crore compared to Rs 8.35 crore in the previous year (about 70% drop). The company swung to a net loss of Rs 4 lakh from a profit of Rs 2.46 lakh in FY2025. The statutory auditor Mayur Shah & Associates issued an unmodified opinion but flagged significant concerns including their own resignation dated 14-02-2026 (not accepted by management citing SEBI rules). The auditor highlighted that Rs 19.45 crore raised via preferential allotment in July 2024 for working capital was actually used for investment activities, and multiple balance confirmations remain unverified with third parties. No bank defaults or debt service issues were reported.
The sharp revenue decline and operational loss combined with auditor resignation and fund diversion concerns present serious red flags for investors. Despite clean equity of Rs 33.74 crore, the company faces governance and operational challenges that could pressure the stock.